Shirt a Phobia

Sample Page

Zamicastat (INNTooltip International Nonproprietary Name; developmental code name BIA-5-1058) is a peripherally selective dopamine β-hydroxylase (DBH) inhibitor which is under development for the treatment of pulmonary arterial hypertension (PAH) and heart failure.[1][2] It is structurally related to etamicastat and is said to be an improved version of this drug.[2] As of July 2022, zamicastat is in phase 2 clinical trials for PAH and phase 1 clinical trials for heart failure.[1] However, no recent development has been reported for heart failure.[1]

See also

References

  1. ^ a b c “Zamicastat”. AdisInsight. 28 July 2022. Retrieved 21 October 2024.
  2. ^ a b Dey SK, Saini M, Prabhakar P, Kundu S (September 2020). “Dopamine β hydroxylase as a potential drug target to combat hypertension”. Expert Opin Investig Drugs. 29 (9): 1043–1057. doi:10.1080/13543784.2020.1795830. PMID 32658551.